诺华：面临更严峻考验，专利损失和管线挫折加剧 (NYSE:NVS)
· seekingalpha.com
诺华2026年第二季度营收144亿美元，新药强劲需求基本被仿制药竞争抵消。详见为何NVS股票评级为持有。
I am an Investment Research Analyst with a strong interest in fundamental equity research, valuation, and long-term investing, with a primary focus on the U.S. ...